千红制药(002550) - 2024 Q2 - 季度业绩预告

Financial Performance - The net profit attributable to shareholders for the first half of 2024 is expected to be 182.79 million yuan, representing a year-on-year increase of 53.57% compared to 119.03 million yuan in the same period last year[3] - The net profit after deducting non-recurring gains and losses is projected to be 179.46 million yuan, an increase of 60.64% from 111.71 million yuan in the previous year[3] - The basic earnings per share is expected to be 0.15 yuan, up from 0.09 yuan in the same period last year[3] Operational Efficiency - The company has experienced a significant improvement in gross margin and a gradual decrease in sales expense ratio during the reporting period[5] Forecast and Assumptions - The performance forecast is based on preliminary calculations by the company's finance department and has not been audited by an accounting firm[6]